Antitumoural Immunity in Colorectal Cancer
Antitumoural Immunity in Colorectal Cancer
Patients receiving chronic immunosuppressive therapy have an increased risk of CRC and a worse survival. Patients with PSC are particularly at risk. Immunosuppression should be included along with the other risk factors defined in screening strategies. Screening modalities should be investigated in further clinical trials.
Characterisation of TILs should be done to refine the prognosis of patients with CRC. In stage I and stage II CRC, it should help the decision for an adjuvant therapy. Furthermore, the impact of an immune score is maintained in late-stage tumours, and could help the decision between standard or intensified therapies.
Different strategies for immune therapy are under investigation, and best therapeutic modalities should be defined, as single agents or in combination with standard therapies, in adjuvant or in metastatic settings. Immune therapies are not yet suitable in routine clinical practice; tumour-induced immunosuppression is a major hurdle that will have to be circumvented. A better understanding of the interactions between cancer cells and immune cells should help improve these strategies.
Conclusion
Patients receiving chronic immunosuppressive therapy have an increased risk of CRC and a worse survival. Patients with PSC are particularly at risk. Immunosuppression should be included along with the other risk factors defined in screening strategies. Screening modalities should be investigated in further clinical trials.
Characterisation of TILs should be done to refine the prognosis of patients with CRC. In stage I and stage II CRC, it should help the decision for an adjuvant therapy. Furthermore, the impact of an immune score is maintained in late-stage tumours, and could help the decision between standard or intensified therapies.
Different strategies for immune therapy are under investigation, and best therapeutic modalities should be defined, as single agents or in combination with standard therapies, in adjuvant or in metastatic settings. Immune therapies are not yet suitable in routine clinical practice; tumour-induced immunosuppression is a major hurdle that will have to be circumvented. A better understanding of the interactions between cancer cells and immune cells should help improve these strategies.
Source...